Switzerland-based Roche, a branded medicines manufacturer, plans to invest $50 billion in its U.S. facilities over the next five years, including constructing a gene therapy manufacturing facility in Pennsylvania.
“Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,” Thomas Schinecker, Roche Group CEO, said. “We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the U.S., across both our Pharmaceutical and Diagnostics Divisions. Our investments of $50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the U.S. and around the world.”
The company operates 13 manufacturing and 15 research and development sites in its Pharmaceutical and Diagnostics Divisions. The investments will include expanding and upgrading manufacturing and distribution capabilities as well as existing pharmaceuticals and diagnostics research centers. More than 25,000 employees will be added at 24 sites in eight states.
Facilities will be build in Indiana, Massachusetts and a location that has yet to be decided.
Roche operates in more than 130 countries. In the United States, Genentech is a wholly owned member of the Roche Group.